HC Wainwright Issues Optimistic Outlook for OLMA Earnings

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) – Equities research analysts at HC Wainwright boosted their Q1 2025 earnings per share (EPS) estimates for Olema Pharmaceuticals in a report released on Wednesday, March 19th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings per share of ($0.59) for the quarter, up from their previous forecast of ($0.64). HC Wainwright has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Olema Pharmaceuticals’ current full-year earnings is ($2.33) per share. HC Wainwright also issued estimates for Olema Pharmaceuticals’ Q2 2025 earnings at ($0.70) EPS, Q3 2025 earnings at ($0.82) EPS, Q4 2025 earnings at ($0.92) EPS, FY2025 earnings at ($3.03) EPS, FY2026 earnings at ($3.86) EPS, FY2027 earnings at ($3.60) EPS and FY2028 earnings at ($3.10) EPS.

Separately, Oppenheimer reiterated an “outperform” rating and issued a $25.00 price target (down previously from $30.00) on shares of Olema Pharmaceuticals in a report on Wednesday.

Olema Pharmaceuticals Stock Up 2.7 %

Olema Pharmaceuticals stock opened at $4.23 on Friday. The business’s 50-day simple moving average is $5.09 and its 200 day simple moving average is $8.35. The stock has a market cap of $242.37 million, a price-to-earnings ratio of -1.93 and a beta of 2.11. Olema Pharmaceuticals has a 12-month low of $3.94 and a 12-month high of $16.62.

Olema Pharmaceuticals (NASDAQ:OLMA) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.12.

Insiders Place Their Bets

In other Olema Pharmaceuticals news, major shareholder Bain Capital Life Sciences Inv purchased 300,000 shares of the company’s stock in a transaction dated Wednesday, January 8th. The shares were bought at an average price of $5.76 per share, with a total value of $1,728,000.00. Following the completion of the transaction, the insider now directly owns 7,800,000 shares in the company, valued at $44,928,000. This trade represents a 4.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 19.40% of the company’s stock.

Institutional Investors Weigh In On Olema Pharmaceuticals

A number of hedge funds have recently modified their holdings of OLMA. KLP Kapitalforvaltning AS acquired a new stake in shares of Olema Pharmaceuticals during the fourth quarter worth about $30,000. Hsbc Holdings PLC acquired a new stake in shares of Olema Pharmaceuticals during the fourth quarter worth about $58,000. Teacher Retirement System of Texas acquired a new stake in shares of Olema Pharmaceuticals during the fourth quarter worth about $60,000. Vontobel Holding Ltd. acquired a new stake in shares of Olema Pharmaceuticals during the fourth quarter worth about $62,000. Finally, Virtus ETF Advisers LLC raised its position in Olema Pharmaceuticals by 43.1% in the 4th quarter. Virtus ETF Advisers LLC now owns 10,579 shares of the company’s stock valued at $62,000 after buying an additional 3,185 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.